Study to Assess the Effects of Non Digestible Carbohydrates on Long-Term Glucose Homeostasis in Untreated Prediabetic Subjects (FOS_GLUCOSE)
Primary Purpose
Pre Diabetes, Prediabetic State, Dysglycemia
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Non digestible carbohydrates
Placebo
Sponsored by
About this trial
This is an interventional prevention trial for Pre Diabetes
Eligibility Criteria
Inclusion Criteria:
- Age between 18 and 65 years (limits included);
- BMI between 25 and 34.9 kg/m² (limits included);
- Dysglycemic or prediabetic subjects with no antidiabetic medication (medical or lifestyle (hygiene-dietetic measures or specific regimen treatment);
- Consuming 10 to 20 g quantity of fiber per day (based on the 3-days food diary fulfilled by the subject between V1 and V2 visits);
- Non smoking subject and agreeing to keep this habit unchanged throughout the study;
- Able and willing to participate to the study by complying with the protocol procedures as evidenced by his dated and signed informed consent form;
- Affiliated with a social security scheme;
- Agree to be registered on the volunteers in biomedical research file;
- Fasting venous glycemia ≥ 1 g/L and ≤ 1.25 g/L at V1 visit.
Exclusion Criteria:
- Metabolic disorder such as diabetes, uncontrolled thyroidal trouble or other metabolic disorder;
- Severe chronic disease or Intestinal Bowel Syndrome (IBS) or gastrointestinal disorders found to be inconsistent with the conduct of the study by the investigator;
- History of retinopathy, microalbuminuria, ischemic cardiovascular event in the 6 months before the study;
- Known or a suspected food allergy or intolerance orhypersensitivity to any food ingredient;
- Known or suspected food allergy or intolerance or hypersensitivity to any of the study products' ingredient;
- Pregnant or lactating women or intending to become pregnant within 4 months ahead;
- Women starting hormone replacement therapy or oral contraception (treatment must be stable for at least 3 months);
- History of bariatric surgery;
- History of any surgery in the 3 months before V1 visit or having scheduled any surgery within 4 months ahead;
- Under dietary supplement which could significantly affect parameter(s) followed during the study according to the investigator or stopped in a too short period before the V1 visit (< 3 months);
- Under treatment which could significantly affect parameter(s) followed during the study according to the investigator or stopped less than 3 months before the V1 visit;
- Under antibiotic treatment in the 3 to 6 months before V1 visit, depending on the antibiotic consumed and according to the investigator;
- Significant change in food habits or in physical activity in the 3 months before V1 visit or not agreeing to keep them unchanged throughout the study;
- Current or planned in the next 4 months specific diet (hyper or hypocaloric, vegan, vegetarian…) or stopped less than 3 months before the study;
- Personal history of anorexia nervosa, bulimia or significant eatingdisorders according to the investigator;
- Consuming more than 3 standard drinks of alcoholic beverage daily for men or 2 daily for women or not agreeing to keep his alcohol consumption habits unchanged throughout the study;
- Taking part in another clinical trial or being in the exclusion period of a previous clinical trial;
- Having received, during the last 12 months, indemnities for clinical trial higher or equal to 4500 Euros;
- Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision;
- Psychological or linguistic incapability to sign the informed consent;
- Impossible to contact in case of emergency.
- Fasting blood triglycerides > 3,5 g/L;
- Fasting blood of total cholesterol > 4,5 g/L or HDLc < 0,1 g/L with an abnormality judged as clinically significant according to the investigator;
- Blood ASAT, ALAT or GGT > 3 times ULN (laboratory Upper Limit of Normal);
- Blood urea > 12 mmol/L or creatinine > 125 μmol/L;
- Complete Blood Count (CBC) with hemoglobin < 11 g/L or leucocytes < 3000/mm3 or leucocytes > 16000/mm3.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Test product
Placebo
Arm Description
Food ingredient containing non digestible carbohydrates, in shape of powder
Food ingredient containing containing 95% of maltodextrin
Outcomes
Primary Outcome Measures
Glycated hemoglobin
Change from baseline of Hba1c level (%)
Secondary Outcome Measures
Glycated hemoglobin
Absolute variations of Hba1c level (%)
Fasting glycemia
Change from baseline of fasting glycemia (g/L)
Fasting insulinemia
Change from baseline of fasting insulinemia (mU/L)
Fructosamine
Change from baseline of fructosamine (μmol/L)
Insulin indexes
Change from baseline of HOMA-IR (Homeostasis Model Assessment of Insulin) and QUICKI (Quantitative Insulin sensitivity Check Index) indices
Insulin sensitivity index
Change from baseline of insulin sensitivity index (ISI)
Glycemia level
Change from baseline of glycemia level (g/L)
Incremental Area Under the Curve (iAUC) of glycemia
Change from baseline of iAUC of glycemia (g/L)
Insulinemia
Change from baseline of insulinemia levels (mU/L)
Incremental Area Under the Curve (iAUC) of insulinemia
Change from baseline of iAUC of insulinemia (mU/L)
Glucacon-like Peptide 1 (GLP-1)
Change from baseline of GLP-1 levels (pmol/L)
Bone mineral composition
Change from baseline of bone mineral composition (kg)
Total lean mass
Change from baseline of total lean mass (g and %)
Total fat mass
Change from baseline of total fat mass (g and %)
Bone Mineral Density
Change from baseline of bone mineral density (g/cm2)
Total Body Mass
Change from baseline of total body mass (kg)
Weight
Change from baseline of weight (in kg)
Body Mass Index (BMI)
Change from baseline of BMI (in kg/m2)
Waist and Hip measurement
Change from baseline of waist and hip Circumference (in cm)
Anthropometric ratios
Change from baseline of Waist to Hip ratio and Waist to Height ratio
Satiety and Appetite sensation
Change on satiety and appetite sensation using 100-mm VAS to complete 15 min before the meal, 30 min, 60 min, 120 min, 180 min and 240 min after the meal at which study product was consumed
Total energy intake
Change from baseline of total energy intake - TEI (kcal/day)
Energy intake
Change from baseline of percentage of energy intake from fat, carbohydrates and protein (g and %TEI)
Fiber intake
Change from baseline of percentage of percentage of fiber (g)
Alcohol intake
Change from baseline of percentage of percentage of alcohol intake (absolute quantities, g/day)
Biomarker of inflammation
Change from baseline of high-sensitivity C-reactive Protein (CRPhs) (mg/L)
Intestinal microbiota composition
Change from baseline microbiota composition for alpha-diversity indices (Shannon and Chao indices) and abundances at the phylum, family and genus level assessed by 16S metabarcoding (in a subgroup of 30 subjects only)
Fecal Short-Chain Fatty Acids (SCFA)
Change from baseline of fermentative activity of the intestinal microbiota assessed by measuring short-chain fatty acids concentrations in stool (in the same subgroup of 30 subjects only)
Full Information
NCT ID
NCT04767672
First Posted
February 19, 2021
Last Updated
March 11, 2021
Sponsor
Tereos
Collaborators
Biofortis, Merieux NutriSciences
1. Study Identification
Unique Protocol Identification Number
NCT04767672
Brief Title
Study to Assess the Effects of Non Digestible Carbohydrates on Long-Term Glucose Homeostasis in Untreated Prediabetic Subjects
Acronym
FOS_GLUCOSE
Official Title
Randomized, Double-Blinded, Placebo-Controlled Study to Assess the Effects of Short-Chain Fructo-Oligosaccharides on Long-Term Glucose Homeostasis in Untreated Prediabetic Subjects
Study Type
Interventional
2. Study Status
Record Verification Date
March 2021
Overall Recruitment Status
Unknown status
Study Start Date
March 2021 (Anticipated)
Primary Completion Date
July 2023 (Anticipated)
Study Completion Date
July 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Tereos
Collaborators
Biofortis, Merieux NutriSciences
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This clinical study aims to prove that the efficacy of non digestible carbohydrates supplementation (daily dose of 20 grams consumed twice a day for 12 weeks) on the regulation of glucose homeostasis is superior than placebo in prediabetic subjects.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pre Diabetes, Prediabetic State, Dysglycemia, PreDiabetes
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
multicentre randomized, parallel arms, double-blind, placebo-controlled clinical trial
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
70 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Test product
Arm Type
Experimental
Arm Description
Food ingredient containing non digestible carbohydrates, in shape of powder
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Food ingredient containing containing 95% of maltodextrin
Intervention Type
Dietary Supplement
Intervention Name(s)
Non digestible carbohydrates
Intervention Description
the subjects will consume 2 bags of 10 grams per day of the product: 1 bag in the morning and 1 bag at lunch or in the evening, at the beginning of the meal, diluted in a large glass of beverage, during 12 weeks.
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
the subjects will consume 2 bags of 10 grams per day of the product: 1 bag in the morning and 1 bag at lunch or in the evening, at the beginning of the meal, diluted in a large glass of beverage, during 12 weeks.
Primary Outcome Measure Information:
Title
Glycated hemoglobin
Description
Change from baseline of Hba1c level (%)
Time Frame
V2 (randomization) and V5 (12 weeks of intervention)
Secondary Outcome Measure Information:
Title
Glycated hemoglobin
Description
Absolute variations of Hba1c level (%)
Time Frame
V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)
Title
Fasting glycemia
Description
Change from baseline of fasting glycemia (g/L)
Time Frame
V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)
Title
Fasting insulinemia
Description
Change from baseline of fasting insulinemia (mU/L)
Time Frame
V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)
Title
Fructosamine
Description
Change from baseline of fructosamine (μmol/L)
Time Frame
V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)
Title
Insulin indexes
Description
Change from baseline of HOMA-IR (Homeostasis Model Assessment of Insulin) and QUICKI (Quantitative Insulin sensitivity Check Index) indices
Time Frame
V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)
Title
Insulin sensitivity index
Description
Change from baseline of insulin sensitivity index (ISI)
Time Frame
V2 (randomization) and V5 (12 weeks of intervention)
Title
Glycemia level
Description
Change from baseline of glycemia level (g/L)
Time Frame
V2 (randomization) and V5 (12 weeks of intervention)
Title
Incremental Area Under the Curve (iAUC) of glycemia
Description
Change from baseline of iAUC of glycemia (g/L)
Time Frame
V2 (randomization) and V5 (12 weeks of intervention)
Title
Insulinemia
Description
Change from baseline of insulinemia levels (mU/L)
Time Frame
V2 (randomization) and V5 (12 weeks of intervention)
Title
Incremental Area Under the Curve (iAUC) of insulinemia
Description
Change from baseline of iAUC of insulinemia (mU/L)
Time Frame
V2 (randomization) and V5 (12 weeks of intervention)
Title
Glucacon-like Peptide 1 (GLP-1)
Description
Change from baseline of GLP-1 levels (pmol/L)
Time Frame
V2 (randomization) and V5 (12 weeks of intervention)
Title
Bone mineral composition
Description
Change from baseline of bone mineral composition (kg)
Time Frame
V2 (randomization) and V5 (12 weeks of intervention)
Title
Total lean mass
Description
Change from baseline of total lean mass (g and %)
Time Frame
V2 (randomization) and V5 (12 weeks of intervention)
Title
Total fat mass
Description
Change from baseline of total fat mass (g and %)
Time Frame
V2 (randomization) and V5 (12 weeks of intervention)
Title
Bone Mineral Density
Description
Change from baseline of bone mineral density (g/cm2)
Time Frame
V2 (randomization) and V5 (12 weeks of intervention)
Title
Total Body Mass
Description
Change from baseline of total body mass (kg)
Time Frame
V2 (randomization) and V5 (12 weeks of intervention)
Title
Weight
Description
Change from baseline of weight (in kg)
Time Frame
V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)
Title
Body Mass Index (BMI)
Description
Change from baseline of BMI (in kg/m2)
Time Frame
V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)
Title
Waist and Hip measurement
Description
Change from baseline of waist and hip Circumference (in cm)
Time Frame
V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)
Title
Anthropometric ratios
Description
Change from baseline of Waist to Hip ratio and Waist to Height ratio
Time Frame
V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)
Title
Satiety and Appetite sensation
Description
Change on satiety and appetite sensation using 100-mm VAS to complete 15 min before the meal, 30 min, 60 min, 120 min, 180 min and 240 min after the meal at which study product was consumed
Time Frame
V2 (randomization) and V5 (12 weeks of intervention)
Title
Total energy intake
Description
Change from baseline of total energy intake - TEI (kcal/day)
Time Frame
V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)
Title
Energy intake
Description
Change from baseline of percentage of energy intake from fat, carbohydrates and protein (g and %TEI)
Time Frame
V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)
Title
Fiber intake
Description
Change from baseline of percentage of percentage of fiber (g)
Time Frame
V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)
Title
Alcohol intake
Description
Change from baseline of percentage of percentage of alcohol intake (absolute quantities, g/day)
Time Frame
V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)
Title
Biomarker of inflammation
Description
Change from baseline of high-sensitivity C-reactive Protein (CRPhs) (mg/L)
Time Frame
V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)
Title
Intestinal microbiota composition
Description
Change from baseline microbiota composition for alpha-diversity indices (Shannon and Chao indices) and abundances at the phylum, family and genus level assessed by 16S metabarcoding (in a subgroup of 30 subjects only)
Time Frame
V2 (randomization) and V5 (12 weeks of intervention)
Title
Fecal Short-Chain Fatty Acids (SCFA)
Description
Change from baseline of fermentative activity of the intestinal microbiota assessed by measuring short-chain fatty acids concentrations in stool (in the same subgroup of 30 subjects only)
Time Frame
V2 (randomization) and V5 (12 weeks of intervention)
Other Pre-specified Outcome Measures:
Title
Incidence of adverse events (AEs)
Description
Number of adverse events (including gastro-intestinal symptoms) by subject that appeared during the entire duration of the study
Time Frame
V1 (Inclusion), V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)
Title
Heart Rate (HR)
Description
Change from baseline of HR (bpm)
Time Frame
V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)
Title
Blood pressure
Description
Change from baseline of Systolic Blood Pressure and Diastolic Blood Pressure (mmHg)
Time Frame
V2 (randomization), V3 (4 weeks of intervention), V4 (8 weeks of intervention) and V5 (12 weeks of intervention)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age between 18 and 65 years (limits included);
BMI between 25 and 34.9 kg/m² (limits included);
Dysglycemic or prediabetic subjects with no antidiabetic medication (medical or lifestyle (hygiene-dietetic measures or specific regimen treatment);
Consuming 10 to 20 g quantity of fiber per day (based on the 3-days food diary fulfilled by the subject between V1 and V2 visits);
Non smoking subject and agreeing to keep this habit unchanged throughout the study;
Able and willing to participate to the study by complying with the protocol procedures as evidenced by his dated and signed informed consent form;
Affiliated with a social security scheme;
Agree to be registered on the volunteers in biomedical research file;
Fasting venous glycemia ≥ 1 g/L and ≤ 1.25 g/L at V1 visit.
Exclusion Criteria:
Metabolic disorder such as diabetes, uncontrolled thyroidal trouble or other metabolic disorder;
Severe chronic disease or Intestinal Bowel Syndrome (IBS) or gastrointestinal disorders found to be inconsistent with the conduct of the study by the investigator;
History of retinopathy, microalbuminuria, ischemic cardiovascular event in the 6 months before the study;
Known or a suspected food allergy or intolerance orhypersensitivity to any food ingredient;
Known or suspected food allergy or intolerance or hypersensitivity to any of the study products' ingredient;
Pregnant or lactating women or intending to become pregnant within 4 months ahead;
Women starting hormone replacement therapy or oral contraception (treatment must be stable for at least 3 months);
History of bariatric surgery;
History of any surgery in the 3 months before V1 visit or having scheduled any surgery within 4 months ahead;
Under dietary supplement which could significantly affect parameter(s) followed during the study according to the investigator or stopped in a too short period before the V1 visit (< 3 months);
Under treatment which could significantly affect parameter(s) followed during the study according to the investigator or stopped less than 3 months before the V1 visit;
Under antibiotic treatment in the 3 to 6 months before V1 visit, depending on the antibiotic consumed and according to the investigator;
Significant change in food habits or in physical activity in the 3 months before V1 visit or not agreeing to keep them unchanged throughout the study;
Current or planned in the next 4 months specific diet (hyper or hypocaloric, vegan, vegetarian…) or stopped less than 3 months before the study;
Personal history of anorexia nervosa, bulimia or significant eatingdisorders according to the investigator;
Consuming more than 3 standard drinks of alcoholic beverage daily for men or 2 daily for women or not agreeing to keep his alcohol consumption habits unchanged throughout the study;
Taking part in another clinical trial or being in the exclusion period of a previous clinical trial;
Having received, during the last 12 months, indemnities for clinical trial higher or equal to 4500 Euros;
Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision;
Psychological or linguistic incapability to sign the informed consent;
Impossible to contact in case of emergency.
Fasting blood triglycerides > 3,5 g/L;
Fasting blood of total cholesterol > 4,5 g/L or HDLc < 0,1 g/L with an abnormality judged as clinically significant according to the investigator;
Blood ASAT, ALAT or GGT > 3 times ULN (laboratory Upper Limit of Normal);
Blood urea > 12 mmol/L or creatinine > 125 μmol/L;
Complete Blood Count (CBC) with hemoglobin < 11 g/L or leucocytes < 3000/mm3 or leucocytes > 16000/mm3.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Marion LIGNER
Phone
0240205799
Email
marion.ligner@mxns.com
First Name & Middle Initial & Last Name or Official Title & Degree
Biofortis Nutrisciences
Phone
0240205799
Email
fosglucose-study_oc@mxns.com
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Study to Assess the Effects of Non Digestible Carbohydrates on Long-Term Glucose Homeostasis in Untreated Prediabetic Subjects
We'll reach out to this number within 24 hrs